Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 13 of 0 results

Testing effectiveness (Phase 2)Study completedNCT04539938
What this trial is testing

Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

Who this might be right for
HER2 Positive Breast Cancer
Seagen, a wholly owned subsidiary of Pfizer 70
Large-scale testing (Phase 3)Active Not RecruitingNCT04862663
What this trial is testing

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Who this might be right for
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca 893
Large-scale testing (Phase 3)UnknownNCT05755048
What this trial is testing

FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 314
Testing effectiveness (Phase 2)Looking for participantsNCT06686394
What this trial is testing

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

Who this might be right for
Breast NeoplasmsBreast Cancer
Merck Sharp & Dohme LLC 81
Not applicableStudy completedNCT02393924
What this trial is testing

Human Epidermal Growth Factor Receptor 2 (HER2) Positive Unresectable Locally Advanced or Metastatic Breast Cancer Disease Registry Study

Who this might be right for
Breast Cancer
Hoffmann-La Roche 311
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07116824
What this trial is testing

HB1801 Combined Treatment of HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 80
Testing effectiveness (Phase 2)Ended earlyNCT01912963
What this trial is testing

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerMetastatic Breast Cancer
Dana-Farber Cancer Institute 32
Large-scale testing (Phase 3)Looking for participantsNCT07060807
What this trial is testing

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Who this might be right for
Breast Neoplasms
Merck Sharp & Dohme LLC 1,000
Early research (Phase 1)Looking for participantsNCT05098210
What this trial is testing

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Cutaneous Melanoma+22 more
Fred Hutchinson Cancer Center 28
Testing effectiveness (Phase 2)UnknownNCT05334810
What this trial is testing

DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer

Who this might be right for
HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 191
Early research (Phase 1)Ended earlyNCT04060862
What this trial is testing

Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 20
Testing effectiveness (Phase 2)Looking for participantsNCT07182721
What this trial is testing

SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment

Who this might be right for
HER2-positive, Unresectable, Locally Advanced or Metastatic Breast CancerSKB264Inetetamab
Fudan University 48
Testing effectiveness (Phase 2)Looking for participantsNCT07002177
What this trial is testing

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Who this might be right for
Metastatic Breast CancerBreast Cancer Stage IBreast Cancer Stage II+2 more
Forward Pharmaceuticals Co., Ltd. 196